Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer

The HUGO Journal

Official Journal of the Human Genome Organisation

Table 5 Association between BRCA1 and BRCA2 mutation carriers and breast cancer pathology

	BRCA Mutations‡
	BRCA1 (n = 15)		BRCA2 (n = 22)				Unadjusted
	n	Col %	n	Col %	χ²	P-value	OR†	95% CI
LVI (Lymphatic invasion):
Absent/suspicious^a	9	90.0	11	91.7			1.00**
Present	1	10.0	1	8.3	0.02	0.89	1.22	(0.07, 20.00)
Grade:
2	4	36.4	5	38.5			1.00**
3	7	63.6	8	61.5	0.01	0.92	1.10	(0.17,4.81)
Type:
DCIS (Ductal carcinoma In Situ)	1	7.7	7	33.3			1.00**
Invasive	12	92.3	14	66.7	2.93	0.09	6.00	(0.65, 50.00)
Stage:
Stage 0	1	8.3	7	36.8
Stage 1	5	41.7	5	26.3			1.00**
Stage 2, 3	6	50.0	7	36.8	1.28	0.86	1.17	(0.22, 6.08)
T stage (Tumor size):
T0	1	7.7	7	35.0
T1	5	38.5	11	55.0			1.00**
T2	7	53.8	2	10.0	7.52	0.04	7.69	(1.16, 5.00)
N stage (Lymph node involvement)
N0	11	91.7	11	64.7			1.00**
N1 and 2	1	8.3	6	35.3	2.89	0.12	0.17	(0.02,1.61)
ER (Estrogen receptor):
Positive	3	25.0	12	63.2			1.00**
Negative	9	75.0	7	36.8	4.29	0.04	5.14	(1.03, 25.60)
PR (Progesterone receptor):
Positive	3	25.0	8	44.4			1.00**
Negative	9	75.0	10	55.6	1.17	0.28	2.40	(0.48, 11.93)
Cerb 2 (Protein of HER2 Oncogene):
Positive	4	33.3	5	29.4			1.00**
Negative	8	66.7	12	70.6	0.05	0.82	0.83	(0.17, 4.09)
Triple negative (ER⁻/PR⁻/Cerb2⁻):
No	4	33.3	11	64.7			1.00**
Yes	8	67.7	6	35.3	2.77	0.10	3.67	(0.77, 17.43)
Ki67 index (% of growing cells):
<12%	1	100.0	5	55.6
>12%	0	0.0	4	44.4	0.74	0.39	–	–

^aThere were only two BRCA2 with LVI suspicious
Bold figure: P-value <0.05
* Values may not sum to 100% because of missing data
** Referent
‡ Includes 4 bilateral cancers in BRCA1 mutation carriers (27%) and 5 bilateral cancers in BRCA2 mutation carriers (23%)
† Univariate Odd Ratios comparing “Carriers” versus “Non-carriers” (reference group)